Natural course and biology of CML
Top Cited Papers
- 27 March 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 94 (S2), 107-121
- https://doi.org/10.1007/s00277-015-2325-z
Abstract
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t(9;22) chromosomal translocation, resulting in the formation of the Philadelphia (Ph) chromosome containing the BCR-ABL1 gene. As such, diagnosis and monitoring of disease involves detection of BCR-ABL1. It is the BCR-ABL1 protein, in particular its constitutively active tyrosine kinase activity, that forges the pathogenesis of CML. This aberrant kinase signalling activates downstream targets that reprogram the cell to cause uncontrolled proliferation and results in myeloid hyperplasia and ‘indolent’ symptoms of chronic phase (CP) CML. Without successful intervention, the disease will progress into blast crisis (BC), resembling an acute leukaemia. This advanced disease stage takes on an aggressive phenotype and is almost always fatal. The cell biology of CML is also centred on BCR-ABL1. The presence of BCR-ABL1 can explain virtually all the cellular features of the leukaemia (enhanced cell growth, inhibition of apoptosis, altered cell adhesion, growth factor independence, impaired genomic surveillance and differentiation). This article provides an overview of the clinical and cell biology of CML, and highlights key findings and unanswered questions essential for understanding this disease.Keywords
This publication has 178 references indexed in Scilit:
- SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell functionLeukemia, 2012
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CMLCell Stem Cell, 2012
- MYC on the Path to CancerCell, 2012
- Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with ImatinibCancer Cell, 2012
- The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cellsLeukemia, 2011
- Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemiaLeukemia, 2010
- Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemiaEMBO Molecular Medicine, 2010
- miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic BlastsCell, 2010
- BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death thresholdLeukemia, 2008
- Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In VivoCancer Cell, 2007